Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients
Gespeichert in:
| Veröffentlicht in: | Leukemia 2012-01, Vol.26 (1), p.172-177 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 177 |
|---|---|
| container_issue | 1 |
| container_start_page | 172 |
| container_title | Leukemia |
| container_volume | 26 |
| creator | Gruber, F X Ernst, T Porkka, K Engh, R A Mikkola, I Maier, J Lange, T Hochhaus, A |
| description | |
| doi_str_mv | 10.1038/leu.2011.187 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_915629328</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A280302632</galeid><sourcerecordid>A280302632</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-1d3eba23db40dfbdb3881cc9a708396cc34916785e7401e22b7be1095793039b3</originalsourceid><addsrcrecordid>eNpt0Utv1DAUBlALgehQ2LFGERVlQwY_ktheVkN5SIPYwNqynZsZVxl7sJ1F_z2OMqUUVV5EuT5-3Q-h1wSvCWbi4wjTmmJC1kTwJ2hFGt7VbduSp2iFheB1J2lzhl6kdIPxPNk9R2eUiDIIXSHz6dbrg7OpCkOV91DBAeIOvIW50Ouks_POVNr3lXdjWP4iJJeynpXzlTssqL4r52rzfVsdSxV8Ti_Rs0GPCV6dvufo1-frn5uv9fbHl2-bq21tG8FyTXoGRlPWmwb3g-kNE4JYKzXHgsnOWtZI0nHRAm8wAUoNN0CwbLlkmEnDztH7Zd9jDL8nSFkdXLIwjtpDmJKSpO2oZFQU-fY_eROm6MvlCpKSt4x3BV0saKdHUM4PIUdt5y3VFRWYYdoxWtT6EVVGD6WrwcPgSv3Bgst_FuxBj3mfwjhlF3x6CD8s0MaQUoRBHWPpdLxVBKs5eVWSV3PyqiRf-JvTmyZzgP4vvou6gHcnoJPV4xBLfC7du7aTgrakuHpxqUz5HcT75jx68B9Iz8IY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>919975376</pqid></control><display><type>article</type><title>Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Springer Nature - Complete Springer Journals</source><source>Nature Journals Online</source><creator>Gruber, F X ; Ernst, T ; Porkka, K ; Engh, R A ; Mikkola, I ; Maier, J ; Lange, T ; Hochhaus, A</creator><creatorcontrib>Gruber, F X ; Ernst, T ; Porkka, K ; Engh, R A ; Mikkola, I ; Maier, J ; Lange, T ; Hochhaus, A</creatorcontrib><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/leu.2011.187</identifier><identifier>PMID: 21818112</identifier><identifier>CODEN: LEUKED</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Antimitotic agents ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Benzamides ; Biological and medical sciences ; Cancer Research ; Cancer therapies ; Chronic myeloid leukemia ; Cloning ; Critical Care Medicine ; Dasatinib ; Drug Resistance, Neoplasm ; Drug therapy ; Evolution & development ; Genetic aspects ; Health aspects ; Hematologic and hematopoietic diseases ; Hematology ; Humans ; Imatinib Mesylate ; Intensive ; Internal Medicine ; Kinases ; letter-to-the-editor ; Letters to the editor ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Medical sciences ; Medicine ; Medicine & Public Health ; Mutation ; Oncology ; Piperazines - therapeutic use ; Pyrimidines - therapeutic use ; Thiazoles - therapeutic use</subject><ispartof>Leukemia, 2012-01, Vol.26 (1), p.172-177</ispartof><rights>Macmillan Publishers Limited 2012</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2012 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jan 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c483t-1d3eba23db40dfbdb3881cc9a708396cc34916785e7401e22b7be1095793039b3</citedby><cites>FETCH-LOGICAL-c483t-1d3eba23db40dfbdb3881cc9a708396cc34916785e7401e22b7be1095793039b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/leu.2011.187$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/leu.2011.187$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25698251$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21818112$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gruber, F X</creatorcontrib><creatorcontrib>Ernst, T</creatorcontrib><creatorcontrib>Porkka, K</creatorcontrib><creatorcontrib>Engh, R A</creatorcontrib><creatorcontrib>Mikkola, I</creatorcontrib><creatorcontrib>Maier, J</creatorcontrib><creatorcontrib>Lange, T</creatorcontrib><creatorcontrib>Hochhaus, A</creatorcontrib><title>Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients</title><title>Leukemia</title><addtitle>Leukemia</addtitle><addtitle>Leukemia</addtitle><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzamides</subject><subject>Biological and medical sciences</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Chronic myeloid leukemia</subject><subject>Cloning</subject><subject>Critical Care Medicine</subject><subject>Dasatinib</subject><subject>Drug Resistance, Neoplasm</subject><subject>Drug therapy</subject><subject>Evolution & development</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Intensive</subject><subject>Internal Medicine</subject><subject>Kinases</subject><subject>letter-to-the-editor</subject><subject>Letters to the editor</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Piperazines - therapeutic use</subject><subject>Pyrimidines - therapeutic use</subject><subject>Thiazoles - therapeutic use</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpt0Utv1DAUBlALgehQ2LFGERVlQwY_ktheVkN5SIPYwNqynZsZVxl7sJ1F_z2OMqUUVV5EuT5-3Q-h1wSvCWbi4wjTmmJC1kTwJ2hFGt7VbduSp2iFheB1J2lzhl6kdIPxPNk9R2eUiDIIXSHz6dbrg7OpCkOV91DBAeIOvIW50Ouks_POVNr3lXdjWP4iJJeynpXzlTssqL4r52rzfVsdSxV8Ti_Rs0GPCV6dvufo1-frn5uv9fbHl2-bq21tG8FyTXoGRlPWmwb3g-kNE4JYKzXHgsnOWtZI0nHRAm8wAUoNN0CwbLlkmEnDztH7Zd9jDL8nSFkdXLIwjtpDmJKSpO2oZFQU-fY_eROm6MvlCpKSt4x3BV0saKdHUM4PIUdt5y3VFRWYYdoxWtT6EVVGD6WrwcPgSv3Bgst_FuxBj3mfwjhlF3x6CD8s0MaQUoRBHWPpdLxVBKs5eVWSV3PyqiRf-JvTmyZzgP4vvou6gHcnoJPV4xBLfC7du7aTgrakuHpxqUz5HcT75jx68B9Iz8IY</recordid><startdate>20120101</startdate><enddate>20120101</enddate><creator>Gruber, F X</creator><creator>Ernst, T</creator><creator>Porkka, K</creator><creator>Engh, R A</creator><creator>Mikkola, I</creator><creator>Maier, J</creator><creator>Lange, T</creator><creator>Hochhaus, A</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20120101</creationdate><title>Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients</title><author>Gruber, F X ; Ernst, T ; Porkka, K ; Engh, R A ; Mikkola, I ; Maier, J ; Lange, T ; Hochhaus, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-1d3eba23db40dfbdb3881cc9a708396cc34916785e7401e22b7be1095793039b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzamides</topic><topic>Biological and medical sciences</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Chronic myeloid leukemia</topic><topic>Cloning</topic><topic>Critical Care Medicine</topic><topic>Dasatinib</topic><topic>Drug Resistance, Neoplasm</topic><topic>Drug therapy</topic><topic>Evolution & development</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Intensive</topic><topic>Internal Medicine</topic><topic>Kinases</topic><topic>letter-to-the-editor</topic><topic>Letters to the editor</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Piperazines - therapeutic use</topic><topic>Pyrimidines - therapeutic use</topic><topic>Thiazoles - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gruber, F X</creatorcontrib><creatorcontrib>Ernst, T</creatorcontrib><creatorcontrib>Porkka, K</creatorcontrib><creatorcontrib>Engh, R A</creatorcontrib><creatorcontrib>Mikkola, I</creatorcontrib><creatorcontrib>Maier, J</creatorcontrib><creatorcontrib>Lange, T</creatorcontrib><creatorcontrib>Hochhaus, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gruber, F X</au><au>Ernst, T</au><au>Porkka, K</au><au>Engh, R A</au><au>Mikkola, I</au><au>Maier, J</au><au>Lange, T</au><au>Hochhaus, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients</atitle><jtitle>Leukemia</jtitle><stitle>Leukemia</stitle><addtitle>Leukemia</addtitle><date>2012-01-01</date><risdate>2012</risdate><volume>26</volume><issue>1</issue><spage>172</spage><epage>177</epage><pages>172-177</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><coden>LEUKED</coden><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>21818112</pmid><doi>10.1038/leu.2011.187</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-6924 |
| ispartof | Leukemia, 2012-01, Vol.26 (1), p.172-177 |
| issn | 0887-6924 1476-5551 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_915629328 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Springer Nature - Complete Springer Journals; Nature Journals Online |
| subjects | Antimitotic agents Antineoplastic agents Antineoplastic Agents - therapeutic use Benzamides Biological and medical sciences Cancer Research Cancer therapies Chronic myeloid leukemia Cloning Critical Care Medicine Dasatinib Drug Resistance, Neoplasm Drug therapy Evolution & development Genetic aspects Health aspects Hematologic and hematopoietic diseases Hematology Humans Imatinib Mesylate Intensive Internal Medicine Kinases letter-to-the-editor Letters to the editor Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Medicine Medicine & Public Health Mutation Oncology Piperazines - therapeutic use Pyrimidines - therapeutic use Thiazoles - therapeutic use |
| title | Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T19%3A01%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dynamics%20of%20the%20emergence%20of%20dasatinib%20and%20nilotinib%20resistance%20in%20imatinib-resistant%20CML%20patients&rft.jtitle=Leukemia&rft.au=Gruber,%20F%20X&rft.date=2012-01-01&rft.volume=26&rft.issue=1&rft.spage=172&rft.epage=177&rft.pages=172-177&rft.issn=0887-6924&rft.eissn=1476-5551&rft.coden=LEUKED&rft_id=info:doi/10.1038/leu.2011.187&rft_dat=%3Cgale_proqu%3EA280302632%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=919975376&rft_id=info:pmid/21818112&rft_galeid=A280302632&rfr_iscdi=true |